Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research.

Messinger JW, Trémeau F, Antonius D, Mendelsohn E, Prudent V, Stanford AD, Malaspina D.

Clin Psychol Rev. 2011 Feb;31(1):161-8. doi: 10.1016/j.cpr.2010.09.002. Epub 2010 Sep 18. Review.

2.

[The clinic of apathy in schizophrenia: a critical review of the issue].

Yazbek H, Raffard S, Del-Monte J, Pupier F, Larue A, Boulenger JP, Gély-Nargeot MC, Capdevielle D.

Encephale. 2014 Jun;40(3):231-9. doi: 10.1016/j.encep.2013.05.002. Epub 2013 Aug 16. Review. French.

PMID:
23958346
3.

Negative symptoms in schizophrenia: avolition and Occam's razor.

Foussias G, Remington G.

Schizophr Bull. 2010 Mar;36(2):359-69. doi: 10.1093/schbul/sbn094. Epub 2008 Jul 21. Review.

4.
5.

Anhedonia, avolition, and anticipatory deficits: assessments in animals with relevance to the negative symptoms of schizophrenia.

Barnes SA, Der-Avakian A, Markou A.

Eur Neuropsychopharmacol. 2014 May;24(5):744-58. doi: 10.1016/j.euroneuro.2013.10.001. Epub 2013 Oct 14. Review.

6.

Individual negative symptoms and domains - Relevance for assessment, pathomechanisms and treatment.

Kaiser S, Lyne J, Agartz I, Clarke M, Mørch-Johnsen L, Faerden A.

Schizophr Res. 2017 Aug;186:39-45. doi: 10.1016/j.schres.2016.07.013. Epub 2016 Jul 21. Review.

PMID:
27453425
7.

Negative Symptoms in Schizophrenia: Where We have been and Where We are Heading.

Azorin JM, Belzeaux R, Adida M.

CNS Neurosci Ther. 2014 Sep;20(9):801-8. doi: 10.1111/cns.12292. Epub 2014 Jun 16. Review.

PMID:
24931186
8.

Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders.

Foussias G, Agid O, Fervaha G, Remington G.

Eur Neuropsychopharmacol. 2014 May;24(5):693-709. doi: 10.1016/j.euroneuro.2013.10.017. Epub 2013 Nov 11. Review.

PMID:
24275699
9.

Evaluating negative-symptom-like behavioural changes in developmental models of schizophrenia.

Moser P.

Eur Neuropsychopharmacol. 2014 May;24(5):774-87. doi: 10.1016/j.euroneuro.2013.11.004. Epub 2013 Nov 22. Review.

PMID:
24332891
10.

Symptom dimensions in the course of childhood-onset schizophrenia.

Bunk D, Eggers C, Klapal M.

Eur Child Adolesc Psychiatry. 1999;8 Suppl 1:I29-35. Review.

PMID:
10546981
11.

Social functioning as an outcome measure in schizophrenia studies.

Burns T, Patrick D.

Acta Psychiatr Scand. 2007 Dec;116(6):403-18. Epub 2007 Oct 17. Review.

PMID:
17941964
12.

[Evolution of the concept of apathy: the need for a multifactorial approach in schizophrenia].

Del-Monte J, Capdevielle D, Gély-Nargeot MC, Yazbek H, Pupier F, Boulenger JP, Raffard S.

Encephale. 2013 May;39 Suppl 1:S57-63. doi: 10.1016/j.encep.2012.11.005. Epub 2013 Jan 23. Review. French.

PMID:
23351930
13.

The structure of negative symptoms within schizophrenia: implications for assessment.

Blanchard JJ, Cohen AS.

Schizophr Bull. 2006 Apr;32(2):238-45. Epub 2005 Oct 27. Review.

14.

Defining therapeutic benefit for people with schizophrenia: focus on negative symptoms.

Schooler NR, Buchanan RW, Laughren T, Leucht S, Nasrallah HA, Potkin SG, Abi-Saab D, Berardo CG, Bugarski-Kirola D, Blaettler T, Edgar CJ, Nordstroem AL, O'Gorman C, Garibaldi G.

Schizophr Res. 2015 Mar;162(1-3):169-74. doi: 10.1016/j.schres.2014.12.001. Epub 2015 Jan 9. Review.

PMID:
25579053
15.

Diagnosis of schizophrenia: consistency across information sources and stability of the condition.

Harvey PD, Heaton RK, Carpenter WT Jr, Green MF, Gold JM, Schoenbaum M.

Schizophr Res. 2012 Sep;140(1-3):9-14. doi: 10.1016/j.schres.2012.03.026. Epub 2012 Apr 13. Review.

16.

[Lack of insight in schizophrenia: a review. Part I: theoretical concept, clinical aspects and Amador's model].

Raffard S, Bayard S, Capdevielle D, Garcia F, Boulenger JP, Gely-Nargeot MC.

Encephale. 2008 Dec;34(6):597-605. doi: 10.1016/j.encep.2007.10.008. Epub 2008 Feb 20. Review. French.

PMID:
19081457
17.

Biological, life course, and cross-cultural studies all point toward the value of dimensional and developmental ratings in the classification of psychosis.

Dutta R, Greene T, Addington J, McKenzie K, Phillips M, Murray RM.

Schizophr Bull. 2007 Jul;33(4):868-76. Epub 2007 Jun 11. Review.

18.

Defining and measuring negative symptoms of schizophrenia in clinical trials.

Marder SR, Kirkpatrick B.

Eur Neuropsychopharmacol. 2014 May;24(5):737-43. doi: 10.1016/j.euroneuro.2013.10.016. Epub 2013 Nov 11. Review.

PMID:
24275698
19.

Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: a translational link to humans.

Neill JC, Harte MK, Haddad PM, Lydall ES, Dwyer DM.

Eur Neuropsychopharmacol. 2014 May;24(5):822-35. doi: 10.1016/j.euroneuro.2013.09.011. Epub 2013 Oct 12. Review.

PMID:
24287012
20.

Diagnostic criteria for schizophrenia and related disorders: options for DSM-IV.

Flaum M, Andreasen NC.

Schizophr Bull. 1991;17(1):133-56. Review.

PMID:
2047783

Supplemental Content

Support Center